Klin Farmakol Farm. 2012;26(1):43-48 [Interní Med. 2011; 13(6): 236-240]

Current oral antidiabetic therapy

Zuzana Vlasáková, Terezie Pelikánová
Centrum diabetologie Institutu klinické a experimentální medicíny, Praha

To address the different underlying defects of pathology of type 2 diabetes, a combined therapy of oral antidiabetic agents is essential.

The development of new agents that affect insulin secretion, alpha cell dysfunction, hepatic glucose overproduction and slow down the

progression of beta cell failure, could be considered as an additional objective for the management of diabetes. The early and adequate

combination therapy could provide a long-term effect on good glycaemic control an reduce diabetic and cardiovascular complication

in type 2 diabetic patients.

Keywords: diabetes mellitus type 2, insulin secretion, insulin resistence

Published: April 24, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vlasáková Z, Pelikánová T. Current oral antidiabetic therapy. Klin Farmakol Farm. 2012;26(1):43-48.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. DeFronzo RA. Banting Lecture: from the triumvirate to the omnious octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58(4): 773-795. Go to original source... Go to PubMed...
    2. Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association; European Association for Study of Diabetes. Medical Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the study of Diabetes. Diabetes Care 2009; 32(1): 193-203. Go to original source... Go to PubMed...
    3. Fox CS, Lullivan L, D´Agostino RB Sr, Vilson PW. Framingham Heart Study. The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study. Diabetes Care 2004: 27(3): 704-708. Go to original source... Go to PubMed...
    4. Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772. Go to original source... Go to PubMed...
    5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865. Go to original source...
    6. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or gliburide monotherapy. N Engl J Med 2006; 355: 2427-2443. Go to original source... Go to PubMed...
    7. Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007; 30: 389-394. Go to original source... Go to PubMed...
    8. Gerich J, Raskin P, Jean-Louis L, et al. PRESERVE-beta: two year efficacy and safety of initial combination therapy with nateglinide or gliburide plus metformin. Diabetes Care 2005; 28: 2093-2099. Go to original source... Go to PubMed...
    9. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009; 5: 262-269. Go to original source... Go to PubMed...
    10. Ahrén B. Dipeptidyl peptidase-4 inhibitors: Clinical data and clinical implications. Diabetes Care 2007; 30: 1344-1350. Go to original source... Go to PubMed...
    11. Goldstein B, Feinglos M, Lunceford J, et al. Effect of initial combination therapy with sixagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 1979-1987. Go to original source... Go to PubMed...
    12. Ahrén B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 1236-1243. Go to original source... Go to PubMed...
    13. DeFronzo RA, Hissa MN, Gerber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009; 32(9): 1649-1655. Go to original source... Go to PubMed...
    14. Ban K, Hui S, Drucker DJ, et al. Cardiovascular consequence of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens 2009; 3: 245-259. Go to original source... Go to PubMed...
    15. Shaw JS, Wilmot RL, Kilpatrick ES. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med 2007; 24: 1160-1163. Go to original source... Go to PubMed...
    16. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471. Go to original source... Go to PubMed...
    17. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomised trials. JAMA 2007; 298: 1180-1188. Go to original source... Go to PubMed...
    18. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007; 30: 2248-2254. Go to original source... Go to PubMed...
    19. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 2002; 39(Suppl 1): S1-S266.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.